65
As part of the US100m acquisition, Ligand Pharmaceuticals Inc has committed to invest up to US$4m in invIOs Holding AG, Apeiron Biologics AG’s immuno-oncology spin-out. Apeiron shareholders are entitled to additional consideration based on future commercial and regulatory events and to up to US$28m if dinutuximab beta (QarzibaTM) royalties exceed certain predetermined thresholds by either 2030 or 2034 respectively. The monoclonal antibody that specifically homes in at the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells is used as a second-line treatment for children with high-risk